The Extent of Lifestyle-Induced Weight Loss Determines the Risk of Prediabetes and Metabolic Syndrome Recurrence during a 5-Year Follow-Up.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
26 Jul 2022
Historique:
received: 27 06 2022
revised: 18 07 2022
accepted: 23 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 29 7 2022
Statut: epublish

Résumé

It is controversial whether lifestyle-induced weight loss (LIWL) intervention provides long-term benefit. Here, we investigated whether the degree of weight loss (WL) in a controlled LIWL intervention study determined the risk of prediabetes and recurrence of metabolic syndrome (MetS) during a 5-year follow-up. Following LIWL, 58 male participants (age 45−55 years) were divided into four quartiles based on initial WL: Q1 (WL 0−8.1%, n = 15), Q2 (WL 8.1−12.8%, n = 14), Q3 (WL 12.8−16.0%, n = 14), and Q4 (WL 16.0−27.5%, n = 15). We analyzed changes in BMI, HDL cholesterol, triglycerides (TGs), blood pressure, and fasting plasma glucose (FPG) at annual follow-up visits. With a weight gain after LIWL between 1.2 (Q2) and 2.5 kg/year (Q4), the reduction in BMI was maintained for 4 (Q2, p = 0.03) or 5 (Q3, p = 0.03; Q4, p < 0.01) years, respectively, and an increase in FPG levels above baseline values was prevented in Q2−Q4. Accordingly, there was no increase in prediabetes incidence after LIWL in participants in Q2 (up to 2 years), Q3 and Q4 (up to 5 years). A sustained reduction in MetS was maintained in Q4 during the 5-year follow-up. The present data indicate that a greater initial LIWL reduces the risk of prediabetes and recurrence of MetS for up to 5 years.

Identifiants

pubmed: 35893913
pii: nu14153060
doi: 10.3390/nu14153060
pmc: PMC9331424
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : 2051/1-1, IS-67/8-1, IS-67/11-1, IS-67/16-1, SFB854/B26, RTG2408/P7&amp;P9, Projektnummer 236360313 - SFB 1118

Références

Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S175-S179
pubmed: 27993539
Clin Sci (Lond). 2013 Feb;124(4):231-41
pubmed: 23126426
Am J Clin Nutr. 1994 Dec;60(6):861-3
pubmed: 7985625
J Gen Intern Med. 2007 Dec;22(12):1695-703
pubmed: 17922167
Annu Rev Nutr. 2009;29:223-56
pubmed: 19400751
Appl Physiol Nutr Metab. 2022 Apr;47(4):343-356
pubmed: 35061523
J Endocrinol. 2016 Dec;231(3):R77-R99
pubmed: 27935822
Med Clin North Am. 2018 Jan;102(1):183-197
pubmed: 29156185
Int J Obes (Lond). 2008 May;32 Suppl 2:S21-4
pubmed: 18469836
Diabetes. 1991 Jun;40(6):686-92
pubmed: 2040385
Circulation. 2005 Nov 15;112(20):3066-72
pubmed: 16275870
Am J Clin Nutr. 2001 Nov;74(5):579-84
pubmed: 11684524
Metabolites. 2021 Aug 09;11(8):
pubmed: 34436467
Am J Physiol. 1996 Oct;271(4 Pt 1):E755-62
pubmed: 8897865
Sci Rep. 2020 Oct 20;10(1):17855
pubmed: 33082492
Proc Soc Exp Biol Med. 1975 Nov;150(2):546-8
pubmed: 813237
Curr Atheroscler Rep. 2005 Mar;7(2):95-102
pubmed: 15727723
Nutrients. 2022 Apr 12;14(8):
pubmed: 35458158
JAMA. 2008 Jun 4;299(21):2524-32
pubmed: 18523221
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Clin Nutr ESPEN. 2021 Apr;42:90-92
pubmed: 33745626
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38
pubmed: 34964875
Diabetologia. 2003 Feb;46(2):143-72
pubmed: 12627314
Arch Intern Med. 2010 Sep 27;170(17):1566-75
pubmed: 20876408
Acta Diabetol. 1994 Apr;31(1):6-13
pubmed: 8043900
Obesity (Silver Spring). 2014 Jul;22(7):1608-16
pubmed: 24771618
N Engl J Med. 1992 Jan 2;326(1):22-9
pubmed: 1727062
Hypertension. 2003 Nov;42(5):878-84
pubmed: 12975389
Am Psychol. 2007 Apr;62(3):220-33
pubmed: 17469900
Annu Rev Nutr. 2001;21:323-41
pubmed: 11375440
Diabetes Metab Syndr Obes. 2010 Nov 02;3:373-85
pubmed: 21437107
Endocr Rev. 2020 May 1;41(3):
pubmed: 32128581
Br J Pharmacol. 2012 Nov;167(6):1177-94
pubmed: 22725625
Diabetes Care. 2011 Oct;34(10):2152-7
pubmed: 21836103
Sci Rep. 2016 Jul 25;6:30173
pubmed: 27452603
Eur J Clin Invest. 2022 Jul;52(7):e13811
pubmed: 35514242
Curr Obes Rep. 2018 Mar;7(1):37-49
pubmed: 29446036
J Clin Invest. 1995 Sep;96(3):1261-8
pubmed: 7657800
J Am Coll Nutr. 2014;33(5):363-74
pubmed: 25105874
J Clin Endocrinol Metab. 2015 Jan;100(1):235-43
pubmed: 25250633
Obesity (Silver Spring). 2015 Jul;23(7):1353-6
pubmed: 26110890
Lancet Diabetes Endocrinol. 2018 Sep;6(9):714-724
pubmed: 29859908

Auteurs

Silke Zimmermann (S)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, 04103 Leipzig, Germany.

Mandy Vogel (M)

Centre for Pediatric Research, Department Woman and Child Health, Hospital for Children and Adolescents, University of Leipzig, 04103 Leipzig, Germany.

Akash Mathew (A)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, 04103 Leipzig, Germany.

Thomas Ebert (T)

Department of Clinical Science, Intervention and Technology, Division of Renal Medicine, Karolinska Institutet, SE-141 86 Stockholm, Sweden.
Medical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, 04103 Leipzig, Germany.

Rajiv Rana (R)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, 04103 Leipzig, Germany.

Shihai Jiang (S)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, 04103 Leipzig, Germany.

Berend Isermann (B)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, 04103 Leipzig, Germany.

Ronald Biemann (R)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, 04103 Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH